[CAS NO. 722494-26-0] BpV(HOpic)

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [722494-26-0]

Catalog

HY-128693

Brand

MCE

CAS

722494-26-0

DESCRIPTION [722494-26-0]

Overview

MDL	MFCD01862576
Molecular Weight	347.24
Molecular Formula	C6H4K2NO8V
SMILES	O=[V+3]12([O-]3)([O-][O-]1)([O-][O-]2)[N]4=CC(O)=CC=C4C3=O.[2 K+]

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

BpV(HOpic) is a potent and selective inhibitor of PTEN with an IC ₅₀ of 14 nM. Nanocarrier-BpV(HOpic) has neuroprotective activity ^[1] ^[2] .

IC50 & Target

IC50: 14 nM (PTEN) ^[1]

In Vitro

BpV(HOpic) (1 µM) treatment increases cell proliferation and decreases apoptotic rate in MG63 cells received Cisplatin treatment ^[3] .
Bpv(HOpic) (1 µM) enhances migration of C2C12 myoblasts and is associated with activation of PI3K/AKT and MAPK/ERK signalling pathways ^[4] .
BpV(HOpic) (1 µM; 48 hours) promotes the initiation of swine follicle growth and development, similar as in rodent species and humans ^[5] .
Nanocarrier-BpV(HOpic) enhances axonal outgrowth of neurons ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BpV(HOpic) (0.05 mg/kg; i.p.) at reperfusion ameliorates liver ischemia/reperfusion (I/R) injury in vivo ^[6] .
BpV(HOpic) (200 μg/kg; i.p.) exacerbates renal dysfunction and promotes tubular damage in mice with ischemia/reperfusion injury (IRI) ^[7] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats are subjected to partial hepatic ischemia ^[6]
Dosage:	0.05 mg/kg
Administration:	I.p. injections at the start of reperfusion
Result:	Ameliorated reoxygenation injury and reproduced the hepatoprotective effects obtained by adenosine A2A receptor stimulation.

Animal Model:	Male C57BL/6 mice (8-12 weeks old; 20-30 g ) are subjected to renal ischemia ^[7]
Dosage:	200 μg/kg
Administration:	I.p. injections 1 h before ischemia and then administers every 6 h after ischemia for 24 hr
Result:	Raised the level of serum creatinine and blood serum urea nitrogen.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

* The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

H ₂ O : 50 mg/mL ( 143.99 mM ; ultrasonic and warming and heat to 60°C)

DMSO : 2.89 mg/mL ( 8.32 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8799 mL	14.3993 mL	28.7985 mL
5 mM	0.5760 mL	2.8799 mL	5.7597 mL
10 mM	0.2880 mL	1.4399 mL	2.8799 mL

* Please refer to the solubility information to select the appropriate solvent.